Linked Life Data

15251135

Source:http://linkedlifedata.com/resource/pubmed/id/15251135

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-7-14
pubmed:abstractText
B cells play an important role in the pathogenesis of many autoimmune diseases. Selective targeting of these cells has been recently achieved using a chimeric monoclonal antibody against the pan B cell surface marker CD20 (rituximab). This antibody was originally developed for the treatment of non-Hodgkin's lymphoma. It was found to be effective, well tolerated and had a very good safety profile. Recent studies have demonstrated the efficacy of rituximab in several refractory autoimmune disorders including rheumatoid arthritis, systemic lupus erythematosus, immune thrombocytopenic purpura, chronic cold agglutinin disease, IgM-mediated neuropathies and mixed cryoglobulinemia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1471-4892
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
398-402
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
pubmed:affiliation
Centre for Rheumatology, The Middlesex Hospital, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK.
pubmed:publicationType
Journal Article, Review